Cargando…
The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
Glucagon-like peptide-1 (GLP-1), a principal mediator of the postprandial insulinotropic response in health, has a half-life of minutes. The saliva of the Gila monster contains exendin-4, a structural analogue of human GLP-1, but with a much longer half-life. A synthetic preparation of exendin-4, ex...
Autores principales: | Deane, Adam M, Chapman, Marianne J, Horowitz, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219279/ https://www.ncbi.nlm.nih.gov/pubmed/20979668 http://dx.doi.org/10.1186/cc9281 |
Ejemplares similares
-
The gut-brain axis in the critically ill: Is glucagon-like peptide-1 protective in neurocritical care?
por: Plummer, Mark P, et al.
Publicado: (2013) -
Exogenous glucagon-like peptide 1: a potentially novel therapy for the management of hyperglycaemia in the critically ill
por: Deane, A, et al.
Publicado: (2009) -
The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
por: Lee, Michael Y., et al.
Publicado: (2013) -
Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes
por: Deane, Adam M, et al.
Publicado: (2011) -
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study
por: Deane, Adam M, et al.
Publicado: (2009)